Haemonetics Corporation (HAE) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended September 28, 2024 (Fiscal Q2 2025). Haemonetics is a global healthcare company operating in three segments: Plasma, Blood Center, and Hospital. The period was marked by significant strategic activity, including the completion of the Attune Medical acquisition and the issuance of new convertible senior notes.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Revenues | $345.5 million | $318.2 million | $681.7 million | $629.5 million |
| Gross Profit | $187.4 million | $170.5 million | $362.4 million | $337.8 million |
| Gross Margin | 54.2% | 53.6% | 53.2% | 53.7% |
| Operating Income | $51.7 million | $35.3 million | $91.5 million | $89.0 million |
| Net Income | $33.8 million | $24.9 million | $72.2 million | $66.0 million |
| Diluted EPS | $0.66 | $0.48 | $1.40 | $1.28 |
| Cash & Equivalents | $299.3 million | (Balance Sheet data) | ||
| Long-Term Debt | $1,219.5 million | (Balance Sheet data) | ||
| Operating Cash Flow (YTD) | $21.4 million | $118.2 million | (6 Months Ended) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 8.6% QoQ and 8.3% YTD, driven primarily by the Hospital segment (+30.9% QoQ), which benefited from recent acquisitions (OpSens and Attune Medical) and growth in Interventional Technologies. Conversely, the Plasma segment declined 3.0% due to lower volumes in North America, and the Blood Center segment declined 1.6%.
- Operating Income: Operating income surged 46.4% QoQ to $51.7 million, largely due to operating leverage and a $14.1 million gain on the sale of a manufacturing facility in the prior quarter (impacting YTD comparisons). YTD operating income grew 2.8%.
- Expenses: Amortization of acquired intangible assets increased significantly (69.8% QoQ) due to the OpSens and Attune Medical acquisitions. R&D expenses rose 30.5% QoQ due to increased headcount from acquisitions.
- Debt Structure: The company issued $700 million in 2.5% Convertible Senior Notes due 2029. Proceeds were used to repay the revolving credit facility, repurchase $200 million of 2026 Notes (generating a $12.6 million net gain), and fund capped call transactions.
Guidance, Outlook, and Risks
- Acquisitions: The company completed the acquisition of Attune Medical ($187.7 million consideration) to expand its Hospital segment in electrophysiology. The OpSens acquisition ($254.5 million) is also contributing to Hospital segment growth.
- Restructuring: The company continues its "Operational Excellence Program" and "Portfolio Rationalization Initiatives." Cumulative charges under the Operational Excellence Program are estimated between $85.0 million and $90.0 million by the end of fiscal 2025. YTD restructuring costs totaled $9.4 million.
- Share Repurchases: An Accelerated Share Repurchase (ASR) of $75.0 million was executed in August 2024. Approximately $150.0 million remains authorized under the current program.
- Legal & Contingencies: A $8.7 million settlement related to the BIPA class action lawsuit was paid in Q1 2025. A new patent infringement lawsuit was filed by Philips against OpSens in Q4 2024; the company recorded a non-material loss contingency.
- Customer Concentration: The Plasma segment faces volume headwinds due to the transition of a major customer (CSL Plasma), with the non-exclusive supply agreement expiring in December 2025.
Investor Verification Checklist
- Acquisition Integration: Verify the revenue contribution and integration costs associated with the Attune Medical and OpSens acquisitions in future quarters.
- Plasma Segment Outlook: Monitor the impact of the CSL Plasma contract expiration in December 2025 on future revenue stability.
- Debt Maturities: Review the repayment schedule for the remaining $300 million of 2026 Convertible Notes and the new 2029 Notes.
- Restructuring Progress: Track the execution of the Operational Excellence Program and the realization of cost savings against the $85-$90 million charge estimate.
- Legal Exposure: Monitor the status of the Philips patent litigation against OpSens and any potential impact on the Hospital segment.